Trial reportEuropean journal of pediatrics2010
Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11-21 months.
Trial report in European journal of pediatrics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults.The Cochrane database of systematic reviews · 2014Pooled it
- Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children.Frontiers in immunology · 2022Trial
- Immunogenicity and safety of intramuscular versus subcutaneous administration of a combined measles, mumps, rubella, and varicella vaccine to children 12 to 18 months of age.Human vaccines & immunotherapeutics · 2019Trial
- Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant.NPJ vaccines · 2022Article
- In vivo fate and intracellular trafficking of vaccine delivery systems.Advanced drug delivery reviews · 2022Review
- Subcutaneous vaccine administration - an outmoded practice.Human vaccines & immunotherapeutics · 2021Review
- Route of Vaccine Administration Alters Antigen Trafficking but Not Innate or Adaptive Immunity.Cell reports · 2020Article
- Persistence of Vaccine-Induced Immunity in Preschool Children: Effect of Gestational Age.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Needle-free delivery of measles virus vaccine to the lower respiratory tract of non-human primates elicits optimal immunity and protection.NPJ vaccines · 2017Article
- Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer.Therapeutic advances in urology · 2015Article
- Effect of vaccine administration modality on immunogenicity and efficacy.Expert review of vaccines · 2015Review
- Surveillance of adverse events following immunization with meningococcal group C conjugate vaccine: Tuscany, 2005-2012.Journal of preventive medicine and hygiene · 2014Article
- A questionnaire-based survey on the uptake and use of cattle vaccines in the UK.Veterinary record open · 2014Article
- Article
- Statement on Measles-Mumps-Rubella-Varicella Vaccine: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)Canada communicable disease report = Releve des maladies transmissibles au Canada · 2010Article
- A previously treated severe haemophilia A patient developed high-titre inhibitor after vaccinations.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study compared intramuscular and subcutaneous administration of two doses of measles-mumps-rubella-varicella (MMRV) combination vaccine (Priorix-Tetra, GlaxoSmithKline Biologicals) in children. Healthy children (N = 328) were randomised to receive MMRV either intramuscularly or subcutaneously. Reactogenicity was similar between treatment groups for immediate vaccination pain, vaccination site pain, redness and incidence of fever and rashes. Slightly less vaccination site swelling occurred during days 0-3 of the post-vaccination period after intramuscular administration. Seroconversion rates for all components, 42-56 days post-dose 2, ranged from 99.3% to 100% in the intramuscular group and from 98.6% to 100% in the subcutaneous. Cell-mediated immunity data supported the humoral immunogenicity findings. In summary, the MMRV vaccine is well tolerated and highly immunogenic when administered either subcutaneously or intramuscularly to children in the second year of life.
Indexed as
Identifiers
20148263What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.